转移性乳腺癌
生物能学
二甲双胍
癌症研究
癌症
苯甲双胍
生物
乳腺癌
肺癌
医学
癌细胞
线粒体
转移
内科学
内分泌学
细胞生物学
糖尿病
作者
Sylvia Andrzejewski,Eva Klimčáková,Radia Marie Johnson,Sébastien Tabariès,Matthew G. Annis,Shawn McGuirk,Jason J. Northey,Valérie Chénard,Urshila Sriram,David Papadopoli,Peter M. Siegel,Julie St‐Pierre
出处
期刊:Cell Metabolism
[Cell Press]
日期:2017-10-11
卷期号:26 (5): 778-787.e5
被引量:215
标识
DOI:10.1016/j.cmet.2017.09.006
摘要
Summary Metabolic adaptations play a key role in fueling tumor growth. However, less is known regarding the metabolic changes that promote cancer progression to metastatic disease. Herein, we reveal that breast cancer cells that preferentially metastasize to the lung or bone display relatively high expression of PGC-1α compared with those that metastasize to the liver. PGC-1α promotes breast cancer cell migration and invasion in vitro and augments lung metastasis in vivo . Pro-metastatic capabilities of PGC-1α are linked to enhanced global bioenergetic capacity, facilitating the ability to cope with bioenergetic disruptors like biguanides. Indeed, biguanides fail to mitigate the PGC-1α-dependent lung metastatic phenotype and PGC-1α confers resistance to stepwise increases in metformin concentration. Overall, our results reveal that PGC-1α stimulates bioenergetic potential, which promotes breast cancer metastasis and facilitates adaptation to metabolic drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI